This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Digging in to the Phase 2b data presented at the AAC Conference for Merck's oral PCSK9 inhibitor, MK-0616, in patients with hypercholesterolemia

Ticker(s): MRK

Who's the expert?

Institution: McGill University Health Center

  • Professor of Medicine and Senior Scientist for the Research Institute at McGill University & Chair for the Canadian Registry in Familial Hypercholesterolemia.
  • Treats over 400 patients for hypercholesterolemia.
  • Research focuses on the metabolic and genetic basis of premature coronary artery disease and the role of high density lipoproteins (HDL) in atherosclerosis: PI on several large clinical trials (HOPE-2, homocysteine; JUPITER; REVEAL; IMPROVE-IT).

Interview Questions

The PCSK9 inhibitors in glycerin, even bempedoic acid, got approved based on the LDL lowering initially, and then only subsequently got the outcomes data added to the labels. Is that true in Canada as well, that they can first enter the market based on the lipid lowering?

Added By: slingshot_insights

Even with the data they get from the CVOTs, would a lower cost enable them to expand the PCSK9 market?

Added By: slingshot_insights

If MK-0616 is developed successfully, to what extent would that take away market share from the current PCSK9 inhibitors?

Added By: slingshot_insights

Given what you've seen so far about MK-0616, if you had to rate your level of excitement about this on a one to 10 scale, what number would you choose and why?

Added By: slingshot_insights

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.


*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.